Your GLP-1 options.
Understand the medication, the routine and the care behind it.
The form
Injections and tablets
The routine
Weekly or daily, depending on the medicine.
The evidence
Evidence belongs to the exact product.
Compare the approved products and their own directions below.
On this page
A linked source is not a clinical endorsement. How we handle review and corrections.
Your options
| Medication | How you take it | Average weight loss in its main trial |
|---|---|---|
| Tirzepatide (Zepbound) | Weekly injection | About 21% at the top dose over 72 weeks |
| Semaglutide (Wegovy) | Weekly injection | About 15% over 68 weeks |
| Semaglutide (Wegovy) | Daily tablet | About 14% over 64 weeks |
| Orforglipron (Foundayo) | Daily tablet | About 11% at the top dose over 72 weeks |
Trial averages include people who stopped early. Your result depends on the exact product, dose, duration and individual circumstances. See care and medication pricing for the separate costs.
Who these medications are for
Wegovy, Zepbound and Foundayo are approved for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or sleep apnea. Your clinician confirms that, reviews your history and labs, and decides what's right for you.
Semaglutide and tirzepatide aren't for anyone who is pregnant or planning to be, or who has a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.
What care looks like here
- A free 15-minute call to see whether we're a fit.
- A 45-minute first visit in person, with baseline labs and a written plan.
- The lowest starting dose, stepping up about every four weeks, only when you're ready.
- A check-in every month, in person or by video, with the same clinician.
- An honest conversation about maintenance, because weight tends to return when people stop.
Side effects
The common ones are nausea, constipation, diarrhea and reflux, mostly while the dose is rising. A slower schedule fixes most of it. Rare but serious risks include pancreatitis and gallbladder problems, and your clinician will tell you exactly what to watch for.
Some of the weight lost on these drugs is muscle. We set a protein target and a strength plan from the first visit. See GLP-1 Plus.
What we don't do
We don't prescribe compounded copies of semaglutide or tirzepatide, and we don't offer retatrutide until it's approved. Here's why compounded GLP-1s are a bad bet now.
Questions people ask
How much does GLP-1 treatment cost at Goodmorrow?
Clinical care is planned at $149 a month. Medication is additional and quoted for your exact prescription. The first visit with baseline labs is a separate $199 fee. Follow-up labs, supplies and delivery may also add to the total.
Do you take insurance?
Goodmorrow is exclusively self-pay. We do not bill insurance for visits, labs or medication.
Which GLP-1 is best?
The one you can take consistently. Tirzepatide produced more weight loss than semaglutide head to head. The pills suit people who don't want injections. Your clinician will walk through the tradeoffs with you.
How long do I have to stay on it?
Weight tends to return when people stop, so most people should plan on long-term treatment, sometimes at a lower maintenance dose. We'll talk about that before you start, not after.
Sources
- Research publicationTirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) New England Journal of Medicine, 2022
- Research publicationOnce-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) New England Journal of Medicine, 2021
- Research publicationOral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4) New England Journal of Medicine, 2025
- Research publicationOrforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1) New England Journal of Medicine, 2025
- Manufacturer informationTirzepatide (Zepbound) prescribing information Eli Lilly, Prescribing information checked October 6, 2026
- Secondary sourceSemaglutide (Wegovy) prescribing information Novo Nordisk, Prescribing information checked October 6, 2026
- Manufacturer informationOrforglipron (Foundayo) prescribing information Eli Lilly, Prescribing information checked October 6, 2026
Good days ahead.
Join the opening list for appointment updates.